For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a serious condition, the arrival of Vyndamax and Tafamidis meglumine represents a significant breakthrough . These groundbreaking therapies protect the transthyretin protein, halting its destructive build-up and reducing